Tags

Type your tag names separated by a space and hit enter

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Abstract

BACKGROUND

Since influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae, studies have suggested that pneumococcal vaccination might reduce its occurrence during pandemics. We assessed the effectiveness of pneumococcal polysaccharide vaccination alone and in combination with influenza vaccination in preventing influenza hospitalization during the 2009-2010 pandemic wave and 2010-2011 influenza epidemic.

RESULTS

1187 cases and 2328 controls were included. The adjusted estimate of effectiveness of pneumococcal vaccination in preventing influenza hospitalization was 41% (95% CI 8-62) in all patients and 43% (95% CI 2-78) in patients aged ≥ 65 y. The adjusted effectiveness of dual PPV23 and influenza vaccination was 81% (95% CI 65-90) in all patients and 76% (95% CI 46-90) in patients aged ≥ 65 y. The adjusted effectiveness of influenza vaccination alone was 58% (95% CI 38-72).

METHODS

We conducted a multicenter case-control study in 36 Spanish hospitals. We selected patients aged ≥ 18 y hospitalized with confirmed influenza and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence. Multivariate analysis was performed using conditional logistic regression. Subjects were considered vaccinated if they had received the pneumococcal or seasonal influenza vaccine>14 d (or>7 d for pandemic influenza vaccine) before the onset of symptoms (cases) or the onset of symptoms in matched cases (controls).

CONCLUSIONS

In elderly people and adults with chronic illness, pneumococcal vaccination may reduce hospitalizations during the influenza season. In people vaccinated with both the influenza and pneumococcal vaccines, the benefit in hospitalizations avoided was greater than in those vaccinated only against influenza.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department de Salut Pública; Universitat de Barcelona; Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP); Madrid, Spain.

    , , , , , , , , , , , , , , , ,

    Source

    MeSH

    Adolescent
    Adult
    Aged
    Aged, 80 and over
    Case-Control Studies
    Costs and Cost Analysis
    Female
    Hospitalization
    Humans
    Influenza Vaccines
    Influenza, Human
    Male
    Middle Aged
    Pneumococcal Vaccines
    Pneumonia, Pneumococcal
    Spain
    Young Adult

    Pub Type(s)

    Journal Article
    Multicenter Study
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    23563516

    Citation

    Domínguez, Angela, et al. "Effectiveness of Vaccination With 23-valent Pneumococcal Polysaccharide Vaccine in Preventing Hospitalization With Laboratory Confirmed Influenza During the 2009-2010 and 2010-2011 Seasons." Human Vaccines & Immunotherapeutics, vol. 9, no. 4, 2013, pp. 865-73.
    Domínguez A, Castilla J, Godoy P, et al. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. Hum Vaccin Immunother. 2013;9(4):865-73.
    Domínguez, A., Castilla, J., Godoy, P., Delgado-Rodríguez, M., Saez, M., Soldevila, N., ... Pumarola, T. (2013). Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. Human Vaccines & Immunotherapeutics, 9(4), pp. 865-73. doi:10.4161/hv.23090.
    Domínguez A, et al. Effectiveness of Vaccination With 23-valent Pneumococcal Polysaccharide Vaccine in Preventing Hospitalization With Laboratory Confirmed Influenza During the 2009-2010 and 2010-2011 Seasons. Hum Vaccin Immunother. 2013;9(4):865-73. PubMed PMID: 23563516.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. AU - Domínguez,Angela, AU - Castilla,Jesús, AU - Godoy,Pere, AU - Delgado-Rodríguez,Miguel, AU - Saez,Marc, AU - Soldevila,Núria, AU - Astray,Jenaro, AU - Mayoral,José María, AU - Martín,Vicente, AU - Quintana,José María, AU - González-Candelas,Fernando, AU - Galán,Juan Carlos, AU - Tamames,Sonia, AU - Castro,Ady, AU - Baricot,Maretva, AU - Garín,Olatz, AU - Pumarola,Tomas, AU - ,, Y1 - 2013/04/01/ PY - 2013/4/9/entrez PY - 2013/4/9/pubmed PY - 2014/4/22/medline KW - effectiveness KW - hospitalization KW - influenza vaccine KW - laboratory-confirmed influenza KW - pneumococcal polysaccharide vaccine SP - 865 EP - 73 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 9 IS - 4 N2 - BACKGROUND: Since influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae, studies have suggested that pneumococcal vaccination might reduce its occurrence during pandemics. We assessed the effectiveness of pneumococcal polysaccharide vaccination alone and in combination with influenza vaccination in preventing influenza hospitalization during the 2009-2010 pandemic wave and 2010-2011 influenza epidemic. RESULTS: 1187 cases and 2328 controls were included. The adjusted estimate of effectiveness of pneumococcal vaccination in preventing influenza hospitalization was 41% (95% CI 8-62) in all patients and 43% (95% CI 2-78) in patients aged ≥ 65 y. The adjusted effectiveness of dual PPV23 and influenza vaccination was 81% (95% CI 65-90) in all patients and 76% (95% CI 46-90) in patients aged ≥ 65 y. The adjusted effectiveness of influenza vaccination alone was 58% (95% CI 38-72). METHODS: We conducted a multicenter case-control study in 36 Spanish hospitals. We selected patients aged ≥ 18 y hospitalized with confirmed influenza and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence. Multivariate analysis was performed using conditional logistic regression. Subjects were considered vaccinated if they had received the pneumococcal or seasonal influenza vaccine>14 d (or>7 d for pandemic influenza vaccine) before the onset of symptoms (cases) or the onset of symptoms in matched cases (controls). CONCLUSIONS: In elderly people and adults with chronic illness, pneumococcal vaccination may reduce hospitalizations during the influenza season. In people vaccinated with both the influenza and pneumococcal vaccines, the benefit in hospitalizations avoided was greater than in those vaccinated only against influenza. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/23563516/Effectiveness_of_vaccination_with_23_valent_pneumococcal_polysaccharide_vaccine_in_preventing_hospitalization_with_laboratory_confirmed_influenza_during_the_2009_2010_and_2010_2011_seasons_ L2 - http://www.tandfonline.com/doi/full/10.4161/hv.23090 DB - PRIME DP - Unbound Medicine ER -